Community Pharmacy England met earlier this month in London, with Members reviewing the ongoing work to support implementation of the Community Pharmacy Contractual Framework (CPCF) settlement, alongside strategic work to bolster the sector’s position ahead of future negotiations. During the meeting on 1st May 2025, updates were provided on the work to implement different elements
Read morePharmacy owners have until 11.59pm today (Friday 16th May 2025) to claim an Aspiration payment for the Pharmacy Quality Scheme (PQS) 2025/26 before the window for claiming this payment closes. The Aspiration payment is optional; if pharmacy owners do not want to claim it, it will not impact on the pharmacy owner’s ability to claim
Read moreIn light of surveillance data indicating that circulation of influenza in the community has returned to baseline levels, the Department of Health and Social Care has published an alert to inform prescribers working in primary care and pharmacy teams that antiviral medicines should no longer be prescribed. Community pharmacists should no longer supply antiviral medicines
Read moreFollowing representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has retrospectively adjusted the reimbursement prices of certain products dispensed in March 2025. Under the current price change mechanism, pharmacy owners would have to wait one (or in some cases two months) before any NHS list prices changes are applied to reimbursement of branded products. The delays in reimbursement prices catching
Read morePharmacy teams can help to raise awareness by displaying posters in their pharmacy to remind patients about the savings they can make with prepayment certificates (PPCs). PPCs offer savings for those needing multiple prescription items or when a patient is prescribed a listed HRT medicine. The cost of each type of PPC has been frozen for
Read moreMHRA Class 4 Medicines Defect Notification: Various Chemidex Pharma Ltd Products Drug alert number: EL(25)A/21 Date issued: 13 May 2025 Chemidex Pharma Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in their topical steroid products does not contain all the required safety information. Cartons for the products/batches listed are missing side effect information
Read morePharmacy owners have one week left to claim an Aspiration payment for the Pharmacy Quality Scheme (PQS) 2025/26 as the window for claiming this payment closes at 11.59pm on Friday 16th May 2025. The Aspiration payment is optional; if pharmacy owners do not want to claim it, it will not impact on the pharmacy owner’s
Read moreMHRA Class 4 Medicines Defect Notification: Chloramphenicol 1% w/w Eye Ointment, Blumont Pharma Limited Drug alert number: EL(25)A/20 Date issued: 08 May 2025 Blumont Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of the batch of Chloramphenicol 1% w/w Eye Ointment (POM version only) in
Read moreThe Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance regarding the risk of psychological side effects while taking Kaftrio▼ (Ivacaftor, tezacaftor, elexacaftor). Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals should advise patients
Read moreDepartment of Health and Social Care (DHSC) has issued a medicine supply notification for Buprenorphine (Reletrans®) 5micrograms/hour and 15micrograms/hour transdermal patches. MSN/2025/030 Tier 2 – medium impact Date of issue: 7th May 2025 Buprenorphine (Reletrans®) 5micrograms/hour and 15micrograms/hour transdermal patches are out of stock until early July 2025. Alternative brands of buprenorphine matrix patches (Bunov®,
Read more
